This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brush, J. E. Articles by Goldstein, D. S. Search for Related Content PubMed PubMed Citation Articles by Brush, J. E., Jr Articles by Goldstein, D. S.

Circulation, Vol 79, 836-844, Copyright © 1989 by American Heart Association

ARTICLES

Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy

JE Brush Jr, G Eisenhofer, M Garty, R Stull, BJ Maron, RO Cannon 3d, JA Panza, SE Epstein and DS Goldstein
Cardiology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.

We examined the uptake and release of norepinephrine in the cardiac circulation and other regional vascular beds in 11 patients with hypertrophic cardiomyopathy (HCM) and in 10 control subjects during simultaneous infusion of tracer-labeled norepinephrine and isoproterenol. Cardiac neuronal uptake of norepinephrine was assessed by comparing regional removal of tracer-labeled norepinephrine with that of tracer-labeled isoproterenol (which is not a substrate for neuronal uptake) and by the relation between production of dihydroxyphenylglycol (DHPG), an exclusively intraneuronal metabolite of norepinephrine, and regional spillover of norepinephrine. Cardiac extraction of norepinephrine averaged 59 +/- 17% in the patients with HCM, significantly less than in the control subjects (79 +/- 13%, p less than 0.05), whereas cardiac extraction of isoproterenol was similar in the two groups (13 +/- 23% versus 13 +/- 14%), indicating that neuronal uptake of norepinephrine was decreased in the patients with HCM. The cardiac arteriovenous difference in norepinephrine was significantly larger in the patients with HCM than in the control subjects (73 +/- 77 versus 13 +/- 50 pg/ml, p less than 0.05), as was the product of the arteriovenous difference in norepinephrine and coronary blood flow (7.3 +/- 7.3 versus 0.8 +/- 3.0 ng/min, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M. Shimizu, H. Ino, M. Yamaguchi, H. Terai, K. Hayashi, K. Nakajima, J. Taki, and H. Mabuchi Heterogeneity of Cardiac Sympathetic Nerve Activity and Systolic Dysfunction in Patients with Hypertrophic Cardiomyopathy J. Nucl. Med., January 1, 2002; 43(1): 15 - 20. [Abstract] [Full Text] [PDF]

				S.-T. Li, C. J. Tack, L. Fananapazir, and D. S. Goldstein Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1867 - 1873. [Abstract] [Full Text] [PDF]

				U. Schotten, K. Filzmaier, B. Borghardt, S. Kulka, F. Schoendube, C. Schumacher, and P. Hanrath Changes of beta -adrenergic signaling in compensated human cardiac hypertrophy depend on the underlying disease Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H2076 - H2083. [Abstract] [Full Text] [PDF]

				R. Wolk Arrhythmogenic mechanisms in left ventricular hypertrophy Europace, January 1, 2000; 2(3): 216 - 223. [Abstract] [PDF]

				I. Ostman-Smith, G.o. Wettrell, and T. Riesenfeld A cohort study of childhood hypertrophic cardiomyopathy: Improved survival following high-dose beta-adrenoceptor antagonist treatment J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1813 - 1822. [Abstract] [Full Text] [PDF]

				M. Schafers, H. Lerch, T. Wichter, C. G. Rhodes, A. A. Lammertsma, M. Borggrefe, F. Hermansen, O. Schober, G.u. Breithardt, and P. G. Camici Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia J. Am. Coll. Cardiol., July 1, 1998; 32(1): 181 - 186. [Abstract] [Full Text] [PDF]

				W.-I. Jung, L. Sieverding, J. Breuer, T. Hoess, S. Widmaier, O. Schmidt, M. Bunse, F. van Erckelens, J. Apitz, O. Lutz, et al. 31P NMR Spectroscopy Detects Metabolic Abnormalities in Asymptomatic Patients With Hypertrophic Cardiomyopathy Circulation, June 30, 1998; 97(25): 2536 - 2542. [Abstract] [Full Text] [PDF]

				M. Schafers, D. Dutka, C. G. Rhodes, A. A. Lammertsma, F. Hermansen, O. Schober, and P. G. Camici Myocardial Presynaptic and Postsynaptic Autonomic Dysfunction in Hypertrophic Cardiomyopathy Circ. Res., January 23, 1998; 82(1): 57 - 62. [Abstract] [Full Text] [PDF]